![Jordi Remon: Comparison of treatments in EGFRm NSCLC at ASCO24](https://oncodaily.com/pub/uploads/2024/06/GO8JDVaXsAElnYN-1280x654.jpeg)
Photo taken from Jordi Remon/X
Jun 2, 2024, 10:50
Jordi Remon: Comparison of treatments in EGFRm NSCLC at ASCO24
Jordi Remon, a Thoracic oncologist at CIOCC Barcelona, recently posted on X:
“For patients with EGFRm Osi-Progression NSCLC, there is no homogeneous benefit in PFS with antiangiogenic + io+CT vs CT and no mature OS benefit.
Phase 3 HARMONI-3 trial (ivonescimab (bispecific VEGF/PD1 Ab) + CT vs CT is pending. Data in Chinese patients looks similar to previous (HARMONI-A).”
Source: Jordi Remon/X